Lisa Astor


Niraparib/abiraterone regimen shows early efficacy signals in metastatic prostate cancer

May 14, 2022

A regimen combining the PARP inhibitor and the androgen receptor pathway inhibitor plus prednisone showed promise in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had progressed on prior treatment with an androgen receptor–targeted therapy.